Psychedelics


Blackhawk Growth Appoints New Advisor to Support Expansion into Psychedelics And Mental Health Treatments

October 14th, 2021 - Ryan Allway

Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that Dr. Lahiru Russell from Digital Mind Technology has been appointed as a medical advisor to Blackhawk. Dr. Russell, with over 10 years of experience in clinical trials and research in psycho-oncology, is developing a platform for mindfulness-based interventions to promote […]

Building the DoorDash or UberEats of Psychedelics

October 14th, 2021 - Ryan Allway

The psychedelics industry is rapidly growing, with more than 50 publicly traded companies worth billions of dollars. At the same time, the FDA’s approval of Spravato (esketamine) for treatment-resistant depression and the growing body of clinical evidence could provide further tailwinds for the industry over the coming decade and beyond. Unfortunately, many patients live in […]

Bay Area Mental Health adds Ketamine Assisted Psychotherapy to its Services as the Psychedelic Renaissance Booms Bay Area Mental Health

October 14th, 2021 - Ryan Allway

Campbell, CA | October 14, 2021 09:00 AM Eastern Daylight Time California based mental health clinic, Bay Area Mental Health (BAMH) is officially announcing that they have added Ketamine Assisted Psychotherapy (KAP) to their offerings in order to better serve the needs of Silicon Valley and surrounding areas. Bay Area Mental Health is the first mental health clinic in […]

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

October 13th, 2021 - Ryan Allway

Achieving its second FDA orphan drug designation with ketamine. Building a proprietary ketamine-based product pipeline for rare and near-rare disorders in pain and inflammation. Seeking to enter Phase 2 clinical trial in 2022.   TORONTO, Oct. 13, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics […]

MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Million Clinical Trial

October 13th, 2021 - Ryan Allway

Evaluating the efficacy of psilocybin-assisted psychotherapy in treatment resistant depression   VANCOUVER, BC, Oct. 13, 2021 /CNW/ – MYND Diagnostics Inc., a wholly-owned subsidiary of MYND Life Sciences (CSE: MYND) (OTC: MYNDF) is pleased to announce that the Company’s proprietary biomarker test technology will be a pivotal component of a proposed clinical trial seeking partial funds from a $15 million fund […]

Revitalist Enters USD $1B TMS Market

October 13th, 2021 - Ryan Allway

VANCOUVER, British Columbia, October 13, 2021–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company“) (CSE: CALM) (OTC: RVLWF) is pleased to report that its clinic locations will now work with psychiatric physicians at each clinic location currently offering transcranial magnetic stimulation (“TMS”). This extension to its existing TMS service protocol provides access to care for […]

Clearmind Medicine Files Provisional Patent Application Related to Methods of Drug-Assisted Psychotherapy

October 13th, 2021 - Ryan Allway

TORONTO, Ontario, Oct. 13, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announces that it has filed a provisional patent application (PPA) with the United […]

Filament Health Announces DTC Eligibility and Up-List to the OTCQB Exchange

October 12th, 2021 - Ryan Allway

VANCOUVER, BC, Oct. 12, 2021 /CNW/ – Filament Health Corp. (NEO: FH) (OTCQB: FLHLF) (“Filament” or the “Company”), an exclusively-natural psychedelic drug discovery company, today announced its common shares have been approved for uplisting and trading on the OTCQB® Venture Market (“OTCQB”). The Company has also received approval from the Depository Trust Company (“DTC”) to make the […]

Cybin Files an International Patent Application Covering Psychedelic Delivery Methods

October 12th, 2021 - Ryan Allway

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed an international patent application related to methods for the delivery of psychedelic medications by inhalation and devices for performing those methods.   The application, governed by the Patent Cooperation Treaty (“PCT”), brings […]

Silo Wellness’ Marley One Line of Functional Mushrooms Now Sold On Amazon

October 12th, 2021 - Ryan Allway

TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness” or the “Company”) (CSE: SILO) (OTCQB: SILFF) (FRA: 3K70), a leading global psychedelics company, today announced the listing of its portfolio of Marley One branded mushroom products on multinational e-commerce conglomerate Amazon. Today’s Amazon listing follows the Company’s inking of over $4 million […]

Ehave One of the First Companies to Pioneer the Collection of Certain Data Points, as well as to Seek to Understand How Ketamine Can Potentially Resolve Issues in the Brain Through a Process Called Neuroplasticity

October 12th, 2021 - Ryan Allway

MIAMI, Oct. 12, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it has hired KGK Science Inc., a contract research organization (CRO) that is wholly-owned by KetamineOne Capital Limited (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), to develop the […]

atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)

October 11th, 2021 - Ryan Allway

NEW YORK, Oct. 11, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. PsyProtix is a precision psychiatry company focused on developing therapeutics […]

Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities

October 8th, 2021 - Ryan Allway

Additional lab facility and federal licence application add expanded contract services to portfolio VANCOUVER, BC, Oct. 8, 2021 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce the expansion of its psychedelics research facility with an additional lab and application for federal licensing, […]

Revitalist Signs LOI to Acquire Virginia Ketamine Clinic

October 7th, 2021 - Ryan Allway

VANCOUVER, British Columbia, October 07, 2021–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company“) (CSE: CALM) (CSNX: CALM.CN) (OTC: RVLWF) is pleased to announce that it entered into a non-binding letter of intent (“LOI“) dated October 5, 2021 to acquire a ketamine clinic (“Acquisition“) located in Richmond, Virginia (“Clinic“).   The Clinic was founded in […]

Psyched Wellness Announces Commencement of Next Pre-Clinical Study on AME-1

October 7th, 2021 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – October 7, 2021) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that KGK Science, a licensed contract research organization (CRO) in Canada, is commencing the next pre-clinical trial […]

HAVN Life Files Final Base Shelf Prospectus October 7, 2021 News

October 7th, 2021 - Ryan Allway

VANCOUVER, BC, Oct. 7, 2021 /CNW/ – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) is pleased to announce that it has filed its final short form base shelf prospectus (the “Final Shelf Prospectus“) with the securities commissions in each of the provinces and territories of Canada and received a […]

MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary – MYND Diagnostics Ltd.

October 7th, 2021 - Ryan Allway

MYND Diagnostics was formed to commercialize proprietary biomarker diagnostic tests for patients suffering from MDD, TRD and other psychiatric disorders.   VANCOUVER, BC, Oct. 7, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND” or the “Company“) is pleased to announce the formation of its diagnostic biomarker division with the incorporation of a wholly-owned subsidiary, MYND […]

Blackhawk Growth’s MindBio Therapeutics Brings Digital Mental Health Technology To Psychedelics Clinical Trials

October 7th, 2021 - Ryan Allway

Vancouver, British Columbia – TheNewswire – October 7, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that MindBio Therapeutics is developing a mental health technology platform to integrate with psychedelic treatments in clinical trials in patients suffering pain who are susceptible to depression, existential distress and anxiety. […]

Clearmind Medicine Partners With Clinipace to Commence Processes Towards FDA Approval

October 7th, 2021 - Ryan Allway

The Regulatory affairs and CRO will oversee the Company’s efforts to secure an IND review of MEAI as a potential treatment for Alcohol Use Disorder and binge drinking   Toronto, Ontario, Oct. 07, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0), (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on […]

Silo Pharma achieves milestone – Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology

October 7th, 2021 - Ryan Allway

Englewood Cliffs NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received approval from the DEA to advance the development of their Z-pod technology in combination with Ketamine. Eric Weisblum, […]

Psychedelic Medicine Start Up Clairvoyant Therapeutics Welcomes Biotech, Cannabis Veteran Greg Engel as Director, Names Long Trinh as CFO

October 6th, 2021 - Ryan Allway

VANCOUVER, BC, Oct. 6, 2021 /PRNewswire/ – Clairvoyant Therapeutics (“Clairvoyant”), a Canadian biotech company focused on the development of psychedelic drug therapies for addiction, is pleased to announce Greg Engel has joined the company’s Board of Directors and Long Trinh has joined as Chief Financial Officer (CFO).   Mr. Engel has more than 25 years of global leadership experience in the pharmaceutical, […]

Lobe Announces Krysalis VX Innovations Inc., a Company Equally Owned by Lobe Sciences Ltd. and Virtual Psychedelics Incorporated, Appointment of Interdisciplinary Team of Advisors

October 6th, 2021 - Ryan Allway

Six Thought Leaders Across Arts, Technology, Academic and Industry Sectors to Advise on the Krysalistm Pod Immersive Treatment Experience   Vancouver, British Columbia–(Newsfile Corp. – October 6, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) today announced that Krysalis VX Innovations Inc. (“Krysalis”), the Virtual experience (“VX”)-focused company designing […]

PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease

October 6th, 2021 - Ryan Allway

“KET-LID” trial to evaluate ketamine’s safety and efficacy in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease   TORONTO, Oct. 06, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, announced today that it has initiated its Phase 2 KET-LID clinical trial […]

MindMed Announces Strategic Research Collaboration with Sphere Health

October 5th, 2021 - Ryan Allway

NEW YORK, Oct. 5, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, has agreed to partner with Sphere Health – a physician-founded employee benefits provider targeting treatments for people with severe mental illness – to collect and analyze multimodal data in order to improve the understanding […]

Revitalist Lifestyle Commences Trading in the USA under Ticker RVLWF

October 5th, 2021 - Ryan Allway

VANCOUVER, British Columbia, October 05, 2021–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company“) (CSE: CALM) (CSNX: CALM.CN) (OTC: RVLWF) is pleased to announce it has commenced trading in the United States on OTC Markets Group’s OTC Pink marketplace under the ticker symbol “RVLWF”. OTC Markets is recognized as a leading public financial market for […]

Lobe Sciences to Present at the BioFuture 2021 & MoneyShow Virtual Expo Investor Conferences

October 5th, 2021 - Ryan Allway

Vancouver, British Columbia–(Newsfile Corp. – October 5, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) today announced that Philip Young, CEO and Director, will present virtually at the BioFuture 2021 Conference taking place October 5-6, 2021, and will present virtually at the MoneyShow Virtual Expo taking place October 5-7, […]

Optimi Health Natural Psilocybin Extraction Breakthrough Submitted for Provisional Patent Application

October 5th, 2021 - Ryan Allway

—Company utilizes green chemistry to stabilize natural product with higher yields   VANCOUVER, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to advise of a recent patent […]

Enveric Biosciences Announces Artificial Intelligence Platform, PsyAI™, Has Identified Viable Drug Candidates from its ‘Psybrary’ of Psychedelic Molecular Compounds

October 5th, 2021 - Ryan Allway

– Paving the way to select lead drug candidates for preclinical studies to support clinical evaluation in cancer-related distress – NAPLES, Fla., Oct. 5, 2021 /PRNewswire/ — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced […]

Global Wellness Strategies Shanti Therapeutics Updates and Symbol Change to GWS

October 4th, 2021 - Ryan Allway

The Shanti Therapeutics Focus on Chronic Pain Market with Psychedelics   Vancouver, British Columbia–(Newsfile Corp. – October 4, 2021) – Global Wellness Strategies Inc. (CSE: LOAN) (FSE: O3X4) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“Global” or the “Company”) changes symbol to GWS and introduces Dr. Sud Agarwal BSc, MB ChB, FANZCA, the Chairman of Cannvalate Pty Ltd. and Shanti Therapeutics. […]

Silo Pharma Looks to Become a NASDAQ Biotech

October 4th, 2021 - Ryan Allway

Silo Pharma Inc. (OTCQB: SILO) is a cutting-edge, development-stage biotechnology company focused on merging traditional therapeutics with emerging psychedelic research for people suffering from indicators such as depression, post-traumatic stress disorder, Parkinson’s disease, and other rare neurological disorders, representing billion-dollar markets. The company submitted an initial application to list on the NASDAQ Capital Market—a move […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading